{"filings":[{"id":528277,"accession_number":"0001437749-26-017799","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-05-19T20:45:23+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals secures U.S. commercialization rights to IMPAVIDO® for $4.25M fixed fees","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Eton will pay $4.25M in fixed fees ($125k Jul 2026, then $1.25M Apr 2027, etc.) plus up to $4M in milestone payments based on cumulative net sales.","Royalty rates: 55% of net sales up to $7M/year, 50% above $7M/year; Supplier covers product costs and regulatory, Eton covers sales and marketing.","Exclusive U.S. commercialization rights start September 26, 2026; IMPAVIDO® had 2025 U.S. sales of $8.1M (Symphony Health).","IMPAVIDO® is the first FDA-approved oral therapy for leishmaniasis (visceral, cutaneous, mucosal), a rare parasitic disease.","This expands Eton's rare disease portfolio to eleven commercial products (including ten prior)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442963,"accession_number":"0001437749-26-017063","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-05-14T20:16:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Pharma Q1 product sales $24.3M (+73% YoY); raises FY2026 guidance to >$120M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product sales $24.3M (+73% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.14, Adj. EBITDA $5.7M (24% margin)","Raises full-year 2026 revenue guidance to >$120M from prior $110M; expects ≥30% Adj. EBITDA margin","Launched DESMODA (FDA-approved oral desmopressin solution); acquired and relaunched HEMANGEOL on May 1","Initiated ET-700 clinical study (extended-release zinc acetate for Wilson disease); FDA cleared INCRELEX label harmonization study","Net income of $1.6M vs net loss of $1.6M in Q1 2025; cash $19.7M after $14M HEMANGEOL acquisition"],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":24266000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94890,"accession_number":"0001437749-26-014315","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals launches HEMANGEOL Oral Solution for infantile hemangioma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy.","Exclusively distributed through Anovo Specialty Pharmacy to streamline patient access and therapy initiation.","Eton Cares support includes $0 co-pay for eligible commercially insured patients and expanded assistance programs.","Estimated 5,000-10,000 infants treated annually in the U.S. with HEMANGEOL.","Treatment window is typically 5 weeks to 5 months of age, lasting about 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94889,"accession_number":"0001437749-26-013369","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals initiates ET-700 pilot study for Wilson disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in double-blinded, placebo-controlled trial comparing ET-700 to Galzin and placebo.","Study uses 64Cu PET imaging to assess intestinal copper absorption in 36 healthy volunteers.","Topline results expected H2 2026; positive data could lead to pivotal study in early 2027.","CEO expects peak annual U.S. sales of ET-700 could exceed $100 million if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94888,"accession_number":"0001437749-26-012488","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals appoints Judith Matthews as CFO effective June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Judith Matthews will become CFO on June 1, 2026, succeeding James Gruber who remains through May 31 then six-month consulting.","Annual base salary of $440,000, target bonus 45% of salary, one-time option for 37,000 shares vesting over 4 years.","Matthews was previously CFO of Iterum Therapeutics (2015-2026) and VP Finance at Durata Therapeutics.","Gruber to provide transition support via six-month consulting agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94887,"accession_number":"0001437749-26-012381","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Eton Pharmaceuticals amends credit facility: rate reduced, interest-only extended to Nov 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest rate reduced to SOFR plus 6.55% (from 6.75%); SOFR floor lowered from 5.0% to 2.75%.","Interest-only period extended to November 2026; optional principal payment in May 2026 or deferral.","No fees paid to SWK for amendment; maturity unchanged at December 2027.","Amendment conditions included consummation of Runway/SWK merger; representations and warranties reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107584,"accession_number":"0001437749-26-009060","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Pharma Q4 product sales $21.3M (+83% YoY); guides FY26 rev >$110M, 30%+ EBITDA margin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product sales $21.3M (+83% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.19; Adj. EBITDA $6.2M","Launched DESMODA (first FDA-approved desmopressin oral solution) on March 9, 2026","Acquired U.S. rights to Orphan Drug HEMANGEOL; relaunch May 1, 2026; accretive to 2026 earnings","FY 2026 guidance: revenue >$110M, Adj. EBITDA margin >30%","Cash $25.9M at Dec 31, 2025; net income $1.5M vs loss $5.4M prior year"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107583,"accession_number":"0001437749-26-006209","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Eton Pharma acquires U.S. rights to HEMANGEOL for $14M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Eton pays $14M upfront plus 8% royalty; $1.5M inventory at close and $0.7M in May 2026.","HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma; 2025 sales $11.7M.","Deal financed with cash on hand; expected to be accretive to 2026 earnings.","Pierre Fabre distributes until April 30; Eton commercializes from May 1 via Eton Cares program.","Acquisition gives Eton ten commercial rare-disease products, including recent DESMODA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107582,"accession_number":"0001437749-26-005537","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals receives FDA approval for DESMODA oral solution for central diabetes insipidus","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus in all ages; first approved oral liquid formulation.","Commercial launch expected March 9; product available exclusively through Anovo specialty pharmacy.","Eton estimates >13,000 U.S. patients; potential peak sales of $30-$50M annually.","Patent protection through 2044; product leverages existing pediatric endocrinology rare disease sales team.","Key safety warning: risk of hyponatremia; fluid restriction recommended; contraindicated in moderate to severe renal impairment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107581,"accession_number":"0001437749-26-002605","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals licenses U.S. rights to ultra-rare disease candidate; FDA under review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Licensed product is first/only generic alternative for condition affecting <100 U.S. patients.","Product currently under FDA review; expected approval and launch mid-2026.","Deal aligns with Eton's commercial infrastructure; adds to pipeline of ultra-rare disease products.","CEO cites opportunity to bring improved patient experience via Eton Cares program.","Eton has eight commercial rare disease products and five late-stage candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123943,"accession_number":"0001437749-25-036853","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals presents at Piper Sandler conference; no new material facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management attending Piper Sandler Annual Healthcare Conference on December 4, 2025 in New York.","Corporate slide presentation furnished as Exhibit 99.1; content not provided in this filing.","No financial or operational updates communicated beyond standard investor presentation.","Event is routine investor outreach; no specific numbers or guidance changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123941,"accession_number":"0001437749-25-035597","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K/A","filed_at":"2025-11-18T23:59:59+00:00","items":["2.01","9.01","8.01","9.0"],"status":"ready","headline":"Eton files historical financials for Increlex acquisition; product net sales $18.7M in 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Increlex for $22.5M upfront plus $7.5M inventory; $2.5M payments on 1st & 2nd anniversaries.","Expanded credit facility to $30M, maturity 3 years, SOFR+6.75%; issued warrant for 289,736 shares at $5.32.","Increlex net sales: $18.7M (2023), $15.1M (2022); nine months Sep 2024 $13.0M vs $13.9M prior.","Pro forma combined net loss for nine months Sep 2024: $5.5M vs Eton historical $3.2M.","Increlex net sales exceeded direct expenses: $3.9M in 2023, $4.1M in nine months Sep 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123942,"accession_number":"0001437749-25-033616","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Q3 product sales $22.5M (+129% YoY), non-GAAP EPS $0.04, ET-600 PDUFA Feb 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales of $22.5M, up 129% YoY; 19th consecutive quarter of sequential growth.","GAAP EPS loss $0.07; non-GAAP diluted EPS $0.04; Adjusted EBITDA $2.9M.","ET-600 NDA accepted with PDUFA date February 25, 2026; launch production scheduled.","INCRELEX largest revenue contributor; GALZIN exceeded year-end target of 200 active patients.","Generated $12.0M cash from operations; ending cash balance $37.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":58669000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140605,"accession_number":"0001437749-25-025438","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Q2 product sales $18.9M (+108% YoY); non-GAAP EPS $0.03; raises revenue run-rate guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product sales $18.9M, up 108% YoY; GAAP EPS $(0.10), non-GAAP EPS $0.03.","Adjusted EBITDA $3.1M vs ($1.6M) prior year; adjusted gross margin improved to 75%.","Launched KHINDIVI (hydrocortisone oral solution) in June; INCRELEX reached 100 active patients ahead of year-end guidance.","Company projects $80M annual revenue run rate in Q3, one quarter ahead of prior outlook.","ET-600 NDA accepted with PDUFA date Feb 25, 2026; second patent granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":36210000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140604,"accession_number":"0001437749-25-022298","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharma: FDA accepts NDA for ET-600 desmopressin oral solution; PDUFA Feb 25, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for ET-600 (desmopressin oral solution) with PDUFA target action date of February 25, 2026.","Product has patent protection through 2044; expected to be first oral liquid option for pediatric desmopressin dosing.","CEO states commercial preparation activities already underway for potential launch in Q1 2026.","Caregivers currently must cut tablets or use unapproved compounding pharmacy liquids for pediatric dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158324,"accession_number":"0001437749-25-021383","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals added to Russell 2000 and Russell 3000 Indexes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective after market close June 27, 2025 as part of 2025 annual reconstitution.","CEO Sean Brynjelsen called it a significant milestone recognizing shareholder value.","Addition expands visibility among index fund managers and institutional investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158323,"accession_number":"0001437749-25-020916","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals dismisses auditor Crowe, appoints Grant Thornton","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 13, 2025, Eton dismissed Crowe LLP as its independent auditor.","No disagreements or reportable events occurred during Crowe's tenure (fiscal year 2024).","Audit Committee appointed Grant Thornton LLP as new auditor for fiscal year 2025.","Crowe's audit report for FY 2024 was unqualified; no adverse opinions or modifications.","Company provided Crowe with disclosures; Crowe's letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158322,"accession_number":"0001437749-25-019983","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eton stockholders elect director Paul V. Maier; ratify Crowe LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Paul V. Maier elected as director for three-year term with 11.67M votes for, 2.74M against.","Ratification of Crowe LLP as independent auditor for 2025 approved with 18.89M for, 0.15M against.","Votes reflect standard annual meeting procedural items; no material operational changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158321,"accession_number":"0001437749-25-018698","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharma gets FDA approval for KHINDIVI oral solution; peak sales >$50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["KHINDIVI is the first and only FDA-approved hydrocortisone oral solution for pediatric adrenocortical insufficiency.","Commercial launch expected week of June 2, 2025; product distributed through Anovo specialty pharmacy.","Combined peak sales of KHINDIVI and ALKINDI SPRINKLE expected to exceed $50 million per year.","Indicated for patients 5 years and older; eliminates need to split or crush tablets for accurate dosing.","Eton's rare disease sales team to promote alongside ALKINDI SPRINKLE; Eton Cares program offers $0 co-pay for qualifying patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158320,"accession_number":"0001437749-25-016468","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Q1 revenue $17.3M (+117% YoY); product sales $14.0M (+76%); Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 product sales $14.0M, 76% growth YoY; 17th straight quarter of sequential growth.","GAAP net loss $(0.06) per share; Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M.","Relaunched INCRELEX (ultra-rare pediatric endocrinology) and GALZIN (Wilson disease); ET-400 NDA PDUFA May 28.","Submitted NDA for ET-600 (desmopressin oral solution) after positive pivotal study; expects 10-month FDA review.","Cash $17.4M; generated $2.1M operating cash flow; expects to exit 2025 at ~$80M annual revenue run rate."],"consensus_eps_estimate":0.0918,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":17282000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158317,"accession_number":"0001437749-25-014334","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K/A","filed_at":"2025-05-02T23:59:59+00:00","items":["2.01","9.01","8.01"],"status":"ready","headline":"Eton withdraws SEC waiver request for Increlex financials; expects filing in Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company had requested a waiver from filing historical audited financials and pro forma statements for Increlex.","After discussions with SEC on unique accounting treatment, waiver request was withdrawn.","Eton now expects to prepare and file the required financial statements in Q3 2025.","Several factors could still delay the filing beyond Q3 2025.","Acquisition of Increlex from Ipsen closed on December 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158319,"accession_number":"0001437749-25-013227","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals submits NDA for ET-600 (desmopressin oral solution) for central diabetes insipidus","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA NDA submission for ET-600, a proprietary oral solution of desmopressin for central diabetes insipidus.","Expected 10-month FDA review; potential approval and launch in Q1 2026.","Patent expires in 2044; bioequivalence study in 75 subjects demonstrated PK equivalence to reference product.","Estimated 3,000 pediatric patients in the U.S. with central diabetes insipidus.","Pre-launch commercial activities underway; CEO cites strong physician demand for titratable pediatric dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158318,"accession_number":"0001437749-25-010358","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton out-licenses international rights to Increlex to Esteve for €4M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Esteve pays €4M upfront; license runs up to ten years with option to buy international rights for up to €6M.","Eton supplies Increlex at a fixed transfer price; no change to expected $80M annual revenue run rate exiting 2025.","Deal lets Eton focus on three rare-disease product launches planned in the U.S. for 2025.","Eton eliminates need for significant ex-U.S. commercialization infrastructure investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176700,"accession_number":"0001437749-25-008163","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals files 8-K with Investor Day presentation slides for March 18, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished as Exhibit 99.1 are slides for Eton's virtual Investor Day held March 18, 2025.","No financial results or specific material updates are disclosed in the 8-K body or exhibit text.","The presentation may contain forward-looking statements, but content is not extractable from filing.","Investors should refer to the full slide deck for any operational or pipeline updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176699,"accession_number":"0001437749-25-008137","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Pharma Q4 2024 revenue $11.6M (+59% YoY); net loss narrows to $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record product revenue of $11.6M in Q4 2024, up 59% from Q4 2023; 16th consecutive quarter of sequential growth.","Net loss improved to $0.6M ($0.02/share) vs $2.3M loss ($0.09/share) in Q4 2023.","Closed transformational acquisition of Increlex (relaunched Jan 2025) and acquired Galzin; both tracking ahead of expectations.","Positive pivotal study for ET-600; NDA submission planned April 2025; ET-400 launch inventory ready with PDUFA May 28.","Cash balance $14.9M at Dec 31, 2024; company expects sequential revenue growth to continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176698,"accession_number":"0001437749-25-007615","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ET-600 passes pivotal bioequivalence study; NDA submission expected April 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ET-600 (desmopressin oral solution) met primary endpoint in pivotal bioequivalence study of 75 healthy subjects.","Company expects to submit NDA to FDA in April 2025; if approved, would be only FDA-approved oral liquid desmopressin.","CEO Brynjelsen anticipates potential product launch in Q1 2026; pre-launch commercial activities underway.","ET-600 is a proprietary patented formulation for central diabetes insipidus targeting precise pediatric dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176693,"accession_number":"0001437749-25-006678","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K/A","filed_at":"2025-03-07T23:59:59+00:00","items":["9.01","2.01","8.01"],"status":"ready","headline":"Eton noncompliant with SEC reporting after Increlex acquisition; unable to provide audited financials","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Acquisition of Increlex from Ipsen closed Dec 19, 2024; must be accounted for as business combination.","Historical financial statements for Increlex do not exist; Eton cannot create them.","Filed SEC waiver request for Item 9.01 financial statement requirement.","Noncompliance renders Eton ineligible for Form S-3 and substantially curtails capital raising.","Until waiver granted or financials filed, no new registration statements can be declared effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176697,"accession_number":"0001437749-25-005799","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton launches Galzin (zinc acetate) capsules for Wilson disease maintenance therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Galzin is FDA-approved for maintenance treatment of Wilson disease after chelator therapy; only FDA-approved zinc therapy for Wilson disease.","Exclusive distribution through Optime Care; Eton Cares program offers $0 co-pay, insurance benefits investigation, and educational support.","CEO Sean Brynjelsen states dedicated sales force and patient support aim to expand access beyond unapproved compounded products.","Eton is investing in further R&D to drive meaningful advancements in Wilson disease treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176696,"accession_number":"0001437749-25-003070","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton awarded patent for ET-600 desmopressin oral solution expiring 2044; NDA filing expected Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO granted U.S. Patent No. 12,214,010 covering ET-600's proprietary desmopressin oral solution formulation.","Patent expires in 2044 and is expected to be listed in FDA Orange Book upon product approval.","ET-600 treats diabetes insipidus; no FDA-approved oral liquid currently available for pediatric patients.","Pivotal bioequivalence study ongoing; results expected at end of February 2025.","If positive, NDA filing with FDA anticipated by Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176695,"accession_number":"0001437749-25-002935","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for Eton's ET-400 NDA to May 28, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Original PDUFA date Feb 28, 2025 extended 3 months to May 28, 2025 for FDA review of supplemental info submitted Dec 2024.","Eton states it has fully addressed all FDA questions and there are no outstanding requests.","CEO says standard extension will not significantly affect internal 2025 revenue projections; company remains confident."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176694,"accession_number":"0001437749-25-000109","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Eton acquires Galzin (zinc acetate) for $7.2M; rare disease product for Wilson Disease","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Galzin from Teva Pharmaceuticals for $7.0M at closing plus $0.2M for inventory.","Will pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of first commercial sale.","Galzin is the only FDA-approved zinc maintenance therapy for Wilson Disease; <5,000 U.S. patients.","Eton expects to assume U.S. commercialization in Q1 2025 with its metabolic sales force.","Also acquired European rights; third party commercializes under Wilzin with Eton supplying product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193535,"accession_number":"0001437749-24-038020","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Eton Pharma closes $22.5M Increlex acquisition; expands credit facility","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Increlex (mecasermin) from Ipsen for $22.5M at closing plus $8.7M inventory; $2.5M due on first and second anniversaries.","Credit facility with SWK expanded by $25.7M to $30M, maturity to 3 years, SOFR+6.75%; warrant for 289,736 shares at $5.32 issued.","Increlex is the only FDA/EMA approved treatment for severe primary IGF-1 deficiency in pediatric patients aged 2+.","U.S. available via AnovoRx specialty pharmacy; Eton to commercialize outside U.S. after 6-month transition.","Additional inventory purchase obligation up to EUR 15.0 million over 30 months; transaction financed by cash and credit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193534,"accession_number":"0001437749-24-037689","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharma announces PKU GOLIKE trial shows statistically significant metabolic control improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PKU GOLIKE showed statistically significant reduction in blood Phe (P=0.0002) and increase in Tyr (P=0.0113) vs standard substitutes during overnight fasting.","Average 17.8% reduction in Phe (P=0.0484) and 33.8% increase in Tyr (P=0.0008) from baseline with PKU GOLIKE; standard substitutes led to 27.6% Phe increase.","Study was randomized crossover in pediatric classical PKU patients at Birmingham Children's Hospital; results to be presented at ACMG 2025.","Eton expects data to promote adoption of PKU GOLIKE; product is marketed via existing metabolic sales force."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193533,"accession_number":"0001437749-24-037367","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals raises $7.0M in registered direct offering of 583,334 shares at $12.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Securities Purchase Agreement on Dec 10, 2024 with an institutional investor.","Gross proceeds approximately $7.0 million from sale of 583,334 shares at $12.00 per share.","No placement agent; shares offered under effective S-3 registration statement.","Proceeds intended for funding acquisition opportunities for products or product candidates.","Shares will be issued free of restrictive legends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193532,"accession_number":"0001437749-24-036504","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals appoints Ipek Erdogan-Trinkaus as CCO; cites Increlex closing and ET-400 launch","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ipek Erdogan-Trinkaus appointed Chief Commercial Officer, effective December 3, 2024.","She previously served as GM of Pediatric Endocrinology at Tolmar, leading the FENSOLVI® launch.","CEO Sean Brynjelsen highlights role at a critical time with Increlex closing in late-December and ET-400 launch in early 2025.","Erdogan-Trinkaus brings rare disease commercial experience from Tolmar and other health/wellness companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193531,"accession_number":"0001437749-24-036095","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals acquires U.S. rights to Amglidia (glyburide oral suspension) for neonatal diabetes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["No upfront payment; up to $2.35M in milestone payments plus 14% royalty on net sales.","Amglidia approved by EMA in 2018, has U.S. FDA Orphan Drug Designation.","Targets neonatal diabetes, a rare condition affecting ~300 U.S. patients with no FDA-approved oral treatment.","Eton plans FDA meeting in Q1 2025 and expects NDA submission in 2026.","Eton can terminate within 30 days of FDA meeting minutes without milestone liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193530,"accession_number":"0001437749-24-034557","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Eton Pharma Q3 product sales +40% YoY, first positive GAAP net income from product sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.3M, net income $0.6M ($0.02 diluted EPS); prior year net loss $0.6M.","Product sales $9.8M, up 40% YoY and 8% sequentially; 15th straight quarter of sequential growth.","Entered asset purchase agreement to acquire Increlex from Ipsen, expected to close near year-end 2024 and be accretive to 2025 earnings.","FDA accepted ET-400 NDA with PDUFA date Feb 28, 2025; additional patent granted for ET-400 expiring 2043.","Cash $20.3M; generated $2.9M operating cash flow in Q3; expects positive Q4 cash flow and will fund Increlex with cash on hand and credit facility expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":27364000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193529,"accession_number":"0001437749-24-033729","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharma awarded second patent for ET-400; PDUFA target Feb 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO granted U.S. Patent No. 12,133,914 for ET-400 (liquid hydrocortisone), expiring 2043.","Second patent for ET-400; first patent (US 11,904,046) obtained in February 2024.","Additional U.S. patent application for ET-400 remains under review.","FDA NDA accepted with PDUFA target action date of February 28, 2025.","If approved, ET-400 would be the only FDA-approved liquid hydrocortisone formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193528,"accession_number":"0001437749-24-030557","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Eton Pharma to acquire Increlex from Ipsen for $22.5M upfront plus $7.5M inventory","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Increlex (mecasermin injection) for severe primary IGF-1 deficiency; approved in 40 territories.","Total upfront consideration $30M ($22.5M asset purchase + $7.5M inventory) plus $2.5M on each of first two anniversaries.","Credit facility expanded to $30M from SWK Holdings; interest at SOFR+6.75%; 289,736 warrant shares at $5.32.","Ipsen reported 2023 global sales of €17.3M for Increlex; Eton to immediately commercialize in U.S. after closing.","Closing expected near year-end 2024; all-cash transaction subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209839,"accession_number":"0001437749-24-025569","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Eton Q2 product sales up 40% YoY to $9.1M; ET-400 NDA accepted with Feb 2025 PDUFA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales and royalty revenue $9.1M, up 40% YoY and 14% sequentially; 14th straight quarter of sequential growth.","Net loss of $2.9M ($0.11/share) including $2.0M ET-400 filing fee; prior year net income $4.6M included $5.5M royalty sale.","ALKINDI SPRINKLE revenue grew 63% YoY; Carglumic Acid sales continue to exceed expectations.","NDA for ET-400 (hydrocortisone oral solution) accepted with PDUFA date Feb 28, 2025; launch quantities planned Q4 2024.","Cash $17.7M; generated $1.3M operating cash flow in Q2; expects positive cash flow for remainder of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":17040000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209837,"accession_number":"0001437749-24-024486","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K/A","filed_at":"2024-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eton board sets triennial say-on-pay votes despite shareholder annual preference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board met Aug 1, 2024 and decided to hold say-on-pay votes every three years.","Majority of votes cast at June 11, 2024 annual meeting favored annual frequency.","Decision effective until next shareholder advisory vote on frequency.","No other changes from original 8-K filed June 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209838,"accession_number":"0001437749-24-022736","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharmaceuticals FDA accepts NDA for ET-400 (hydrocortisone oral solution); PDUFA Feb 28, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PDUFA target action date set for February 28, 2025.","ET-400 is a proprietary room-temperature stable hydrocortisone oral solution with patent protection through 2043.","CEO Sean Brynjelsen projects combined peak sales of ET-400 and ALKINDI SPRINKLE to exceed $50 million annually.","Company preparing for potential product launch in early 2025 upon FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228040,"accession_number":"0001437749-24-020967","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":[],"status":"ready","headline":"Eton replaces auditor KMJ Corbin with Crowe after KMJ partners join Crowe; no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KMJ Corbin resigned as independent auditor effective June 14, 2024; Crowe appointed same day with Audit Committee approval.","Partners and professional staff of KMJ joined Crowe, triggering the resignation and appointment.","KMJ's reports for fiscal 2022 and 2023 contained no adverse opinion or modification.","No disagreements or reportable events between Eton and KMJ during those periods or the subsequent interim period.","KMJ provided a letter agreeing with the company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228039,"accession_number":"0001437749-24-019953","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Eton stockholders elect Riedel and Brynjelsen, approve exec comp and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Norbert G. Riedel and Sean E. Brynjelsen re-elected as directors with 8,823,386 and 9,666,679 votes for, respectively.","Advisory vote to approve executive compensation passed: 9,170,839 for, 553,043 against.","Advisory vote on frequency of exec compensation votes: 1-year option received 6,169,483 votes (most frequent).","Ratification of KMJ Corbin & Company LLP as auditor for FY2024 passed with 17,193,502 for, 150,140 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228038,"accession_number":"0001437749-24-015686","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Eton Pharma Q1 revenue $8.0M (+50% YoY); acquires PKU GOLIKE; submits NDA for ET-400","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $8.0M, up 50% YoY; net loss narrowed to $0.8M from $2.7M.","Acquired U.S. rights to PKU GOLIKE for PKU; market ~$100M; targeting $10M annual sales.","Submitted NDA for ET-400 (hydrocortisone oral solution); potential approval Q1 2025; peak sales >$50M combined.","Launched Nitisinone in Feb 2024; $50M market; cross-selling opportunities with Carglumic Acid and PKU GOLIKE."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":7966000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228037,"accession_number":"0001437749-24-013838","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton submits NDA to FDA for ET-400 hydrocortisone oral solution; approval expected Q1 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted for ET-400, a proprietary patented hydrocortisone oral solution.","Company expects 10-month FDA review; potential approval and launch in Q1 2025.","Combined peak sales of ET-400 and Alkindi Sprinkle forecast to exceed $50M annually.","ET-400 has patent protection through 2043; additional patent applications under review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228036,"accession_number":"0001437749-24-012443","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":[],"status":"ready","headline":"Eton cancels $13.1M equity raise and credit expansion after losing Eiger auction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Planned to issue 1,287,500 common shares at $3.50 and pre-funded warrants for 2,462,500 shares.","Also planned to expand credit facility from $21.9M to $27.0M with a lender warrant for 358,976 shares.","All transactions were contingent on winning an auction for Eiger BioPharmaceuticals assets on April 17, 2024.","Eton was not the successful bidder; therefore all agreements were cancelled and are void.","No underwriters were used; the offerings were exempt under Regulation D Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246802,"accession_number":"0001437749-24-008919","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Eton Pharma acquires U.S. rights to PKU GOLIKE for $2.2M upfront plus milestones and 30% royalty","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired U.S. rights to PKU GOLIKE for $2.2M upfront, up to $2M milestones, and 30% royalty on net sales.","PKU GOLIKE targets phenylketonuria (PKU) in an estimated $100M U.S. medical formula market.","Deal expected to be accretive to 2024 earnings; peak sales forecast >$10M annually.","Also acquired U.S. rights to line extensions for tyrosinemia, homocystinuria (launch 2025/2026) and right of first negotiation for RLF-OD032.","Product complements Eton's metabolic franchise; promoted by existing sales force targeting metabolic geneticists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246801,"accession_number":"0001437749-24-007850","cik":1710340,"company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Eton Pharma Q4 revenue up 109% to $7.3M; ET-400 NDA submission planned Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 product sales & royalty revenue $7.3M, up 109% YoY; full-year revenue $26.1M (+132%).","Net loss of $2.3M ($0.09/share) in Q4 vs net income of $0.9M in Q4 2022; operating cash flow positive $0.4M.","ET-400 (oral hydrocortisone) passed pivotal bioequivalence study; NDA submission expected Q2 2024.","ET-600 passed pilot bioequivalence study; pivotal study planned H2 2024, NDA in early 2025.","Launched Nitisinone capsules in Feb 2024; sampling program for ALKINDI SPRINKLE went live."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":881760008.7888888,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}